{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T01:09:37Z","timestamp":1789088977304,"version":"build-2803163510"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":86,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Southern Consortium Node of the National Drug Abuse Treatment Clinical Trials Network","award":["UG1 DA013727"],"award-info":[{"award-number":["UG1 DA013727"]}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"crossref","award":["K12 DA031794"],"award-info":[{"award-number":["K12 DA031794"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Health Resources and Services Administration (HRSA) of the US Department of Health and Human Services","award":["U66RH31458"],"award-info":[{"award-number":["U66RH31458"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Buprenorphine is an effective treatment for Opioid Use Disorder (OUD), but many patients discontinue this medication within six-months of initiation and racial disparities in access and retention in buprenorphine treatment exist. Telemedicine is a potentially promising strategy to improve buprenorphine treatment retention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To determine if, compared to pre-pandemic in-person services, telemedicine visits were associated with increased retention in MOUD treatment at six-months and if there were differences by race.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This is a retrospective cohort study that evaluated medical records of individuals treated for OUD in-person (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009247) and via telemedicine (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009204) at a large academic medical center in the Southeastern United States from 2018 to 2021. The primary outcome was the percentage of patients retained in treatment at six-months, defined as having an outpatient visit associated with a buprenorphine prescription. Chi-squared tests were used to evaluate the percentage of patients retained in treatment at six-months, multivariable logistic regression identified correlates of retention, and Kaplan-Meier survival analyses evaluated time in treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      35.3% of the cohort (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009411;\n                      <jats:italic>M<\/jats:italic>\n                      <jats:sub>\n                        <jats:italic>age<\/jats:italic>\n                      <\/jats:sub>\n                      =38; 64% female; 89% White; 39% Medicaid insured) were retained in treatment within six-months of their index visit. Individuals with telemedicine-based treatment were 1.8 times more likely to be retained in treatment at six-months compared to those with in-person visits (AOR\u2009=\u20091.87, 95% CI\u2009=\u20091.17\u20133.00). Non-White individuals were 2.05 times more likely to remain in treatment at six-months, compared to White individuals (AOR\u2009=\u20092.05, 95% CI\u2009=\u20091.02\u20134.14).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study suggests that retention in treatment may be higher with telemedicine-based buprenorphine treatment compared to in-person care. Non-White patients appeared to experience an even greater benefit, though further research is needed to confirm this finding. As policymakers are determining telehealth prescribing laws, these findings further support the use of telemedicine to improve retention in effective treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13722-026-00682-2","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T16:53:12Z","timestamp":1781715192000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Telemedicine and increased retention in medications for opioid use disorder treatment"],"prefix":"10.1186","volume":"21","author":[{"given":"Allison J.","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara M.","family":"Witcraft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Lane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance","family":"Guille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"682_CR1","unstructured":"Centers for Disease Control and Prevention. Wide-ranging Online Data for Epidemiologic Research (WONDER). National Center for Health Statistics; 2021. http:\/\/wonder.cdc.gov."},{"key":"682_CR2","volume-title":"Medications for opioid use disorder save lives","year":"2019","unstructured":"Mancher M, Leshner AI, editors. Medications for opioid use disorder save lives. Washington, DC: National Academies Press (US); 2019."},{"key":"682_CR3","doi-asserted-by":"crossref","unstructured":"Kariisa M, Davis NL, Kumar S, Seth P, Mattson CL, Chowdhury F, et al. Vital signs: drug overdose deaths, by selected sociodemographic and social determinants of health characteristics\u201425 states and the District of Columbia, 2019\u20132020. Report No.: 2022;71(29):940\u2013947.","DOI":"10.15585\/mmwr.mm7129e2"},{"issue":"8","key":"682_CR4","doi-asserted-by":"publisher","first-page":"e2327488","DOI":"10.1001\/jamanetworkopen.2023.27488","volume":"6","author":"CM Jones","year":"2023","unstructured":"Jones CM, Han B, Baldwin GT, Einstein EB, Compton WM. Use of medication for opioid use disorder among adults with past-year opioid use disorder in the US, 2021. JAMA Netw Open. 2023;6(8):e2327488.","journal-title":"JAMA Netw Open"},{"issue":"10","key":"682_CR5","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.2105\/AJPH.2021.306431","volume":"111","author":"MR Larochelle","year":"2021","unstructured":"Larochelle MR, Slavova S, Root ED, Feaster DJ, Ward PJ, Selk SC, et al. Disparities in opioid overdose death trends by race\/ethnicity, 2018\u20132019, from the Healing Communities Study. Am J Public Health. 2021;111(10):1851\u20134.","journal-title":"Am J Public Health"},{"key":"682_CR6","doi-asserted-by":"publisher","first-page":"107181","DOI":"10.1016\/j.addbeh.2021.107181","volume":"126","author":"S Lane","year":"2022","unstructured":"Lane S, Moreland A, Khan S, Hartwell K, Haynes L, Brady K. Disparities in years of potential life lost to Drug-involved overdose deaths in South Carolina. Addict Behav. 2022;126:107181.","journal-title":"Addict Behav"},{"issue":"4","key":"682_CR7","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1007\/s40615-021-01095-4","volume":"9","author":"AB Parlier-Ahmad","year":"2022","unstructured":"Parlier-Ahmad AB, Pugh M Jr, Martin CE. Treatment Outcomes Among Black Adults Receiving Medication for Opioid Use Disorder. J Racial Ethn Health Disparities. 2022;9(4):1557\u201367. https:\/\/doi.org\/10.1007\/s40615-021-01095-4 . Epub 2021 Jul 12. PMID: 34254271; PMCID: PMC8274965.","journal-title":"J Racial Ethn Health Disparities"},{"issue":"10","key":"682_CR8","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1001\/jamapsychiatry.2022.2284","volume":"79","author":"CM Jones","year":"2022","unstructured":"Jones CM, Shoff C, Hodges K, Blanco C, Losby JL, Ling SM, et al. Receipt of telehealth services, receipt and retention of medications for opioid use disorder, and medically treated overdose among Medicare beneficiaries before and during the COVID-19 pandemic. JAMA Psychiatry. 2022;79(10):981.","journal-title":"JAMA Psychiatry"},{"issue":"10","key":"682_CR9","doi-asserted-by":"publisher","first-page":"e2336914","DOI":"10.1001\/jamanetworkopen.2023.36914","volume":"6","author":"LR Hammerslag","year":"2023","unstructured":"Hammerslag LR, Mack A, Chandler RK, et al. Telemedicine Buprenorphine Initiation and Retention in Opioid Use Disorder Treatment for Medicaid Enrollees. JAMA Netw Open. 2023;6(10):e2336914. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.36914.","journal-title":"JAMA Netw Open"},{"issue":"7","key":"682_CR10","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1080\/10826084.2025.2478603","volume":"60","author":"S Choi","year":"2025","unstructured":"Choi S, Hussain S, Wang Y, D\u2019Aunno T, Mijanovich T, Neighbors CJ. Telehealth Disparities in Outpatient Substance Use Disorder (SUD) Treatment among Medicaid Beneficiaries during COVID-19. Subst Use Misuse. 2025;60(7):1007\u201315. https:\/\/doi.org\/10.1080\/10826084.2025.2478603.","journal-title":"Subst Use Misuse"},{"key":"682_CR11","unstructured":"U.S. Census Bureau. QuickFacts: South Carolina [Internet]. Census.gov; 2025 Mar 6 [cited 2025 Jun 15]. Available from: https:\/\/www.census.gov\/quickfacts\/fact\/table\/SC\/INC110223."},{"issue":"3","key":"682_CR12","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.jemermed.2021.04.007","volume":"61","author":"LK Jennings","year":"2021","unstructured":"Jennings LK, Lane S, McCauley J, Moreland A, Hartwell K, Haynes L, Barth KS, Gainey SS, Brady KT. Retention in treatment after emergency department\u2013initiated buprenorphine. J Emerg Med. 2021;61(3):211\u201321. https:\/\/doi.org\/10.1016\/j.jemermed.2021.04.007.","journal-title":"J Emerg Med"},{"key":"682_CR13","doi-asserted-by":"publisher","first-page":"101289","DOI":"10.1016\/j.ssmph.2022.101289","volume":"20","author":"M DiNardi","year":"2022","unstructured":"DiNardi M, Swann WL, Kim SY. Racial\/ethnic residential segregation and the availability of opioid and substance use treatment facilities in US counties, 2009\u20132019. SSM - Popul Health. 2022;20:101289.","journal-title":"SSM - Popul Health"},{"issue":"6","key":"682_CR14","doi-asserted-by":"publisher","first-page":"e205873","DOI":"10.1001\/jamanetworkopen.2020.5873","volume":"3","author":"ME Reed","year":"2020","unstructured":"Reed ME, Huang J, Graetz I, et al. Patient Characteristics Associated With Choosing a Telemedicine Visit vs Office Visit With the Same Primary Care Clinicians. JAMA Netw Open. 2020;3(6):e205873. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.5873.","journal-title":"JAMA Netw Open"},{"key":"682_CR15","doi-asserted-by":"publisher","first-page":"104612","DOI":"10.1016\/j.drugpo.2024.104612","volume":"133","author":"R Ghonasgi","year":"2024","unstructured":"Ghonasgi R, Paschke ME, Winograd RP, Wright C, Selph E, Banks DE. The intersection of substance use stigma and anti-black racial stigma: A scoping review. Int J Drug Policy. 2024;133:104612. https:\/\/doi.org\/10.1016\/j.drugpo.2024.104612.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"682_CR16","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2190\/PM.48.1.b","volume":"48","author":"P Shore","year":"2014","unstructured":"Shore P, Goranson A, Ward MF, Lu MW. Meeting Veterans Where They\u2019re @: A VA Home-Based Telemental Health (HBTMH) Pilot Program. Int J Psychiatry Med. 2014;48(1):5\u201317. https:\/\/doi.org\/10.2190\/PM.48.1.b. (Original work published 2014).","journal-title":"Int J Psychiatry Med"},{"key":"682_CR17","unstructured":"Substance Abuse and Mental Health Services Administration. Telehealth for the treatment of serious mental illness and substance use disorders (SAMHSA Publication No. PEP21-06-02-001). National Mental Health and Substance Use Policy Laboratory. Substance Abuse and Mental Health Services Administration; 2021. https:\/\/library.samhsa.gov\/sites\/default\/files\/pep21-06-02-001.pdf."},{"issue":"2","key":"682_CR18","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1080\/00952990.2023.2180382","volume":"49","author":"AR Williams","year":"2023","unstructured":"Williams AR, Aronowitz SV, Rowe C, Gallagher R, Behar E, Bisaga A. Telehealth for opioid use disorder: retention as a function of demographics and rurality. Am J Drug Alcohol Abus. 2023;49(2):260\u20135. https:\/\/doi.org\/10.1080\/00952990.2023.2180382.","journal-title":"Am J Drug Alcohol Abus"},{"key":"682_CR19","doi-asserted-by":"crossref","unstructured":"Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550.","DOI":"10.1136\/bmj.j1550"},{"issue":"9","key":"682_CR20","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s40273-016-0400-5","volume":"34","author":"SM Murphy","year":"2016","unstructured":"Murphy SM, Polsky D. Economic evaluations of opioid use disorder interventions. PharmacoEconomics. 2016;34(9):863\u201387.","journal-title":"PharmacoEconomics"},{"key":"682_CR21","doi-asserted-by":"publisher","unstructured":"Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev [Internet]. 2014 Feb 6 [cited 2024 Jan 18];2014(2). Available from: https:\/\/doi.org\/10.1002\/14651858.CD002207.pub4.","DOI":"10.1002\/14651858.CD002207.pub4"},{"key":"682_CR22","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.addbeh.2016.02.030","volume":"58","author":"GJ Stahler","year":"2016","unstructured":"Stahler GJ, Mennis J, DuCette JP. Residential and outpatient treatment completion for substance use disorders in the U.S.: Moderation analysis by demographics and drug of choice. Addict Behav. 2016;58:129\u201335.","journal-title":"Addict Behav"},{"key":"682_CR23","doi-asserted-by":"publisher","first-page":"107732","DOI":"10.1016\/j.drugalcdep.2019.107732","volume":"207","author":"G Lapham","year":"2020","unstructured":"Lapham G, Boudreau DM, Johnson EA, Bobb JF, Matthews AG, McCormack J, et al. Prevalence and treatment of opioid use disorders among primary care patients in six health systems. Drug Alcohol Depend. 2020;207:107732.","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"682_CR24","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1377\/hlthaff.2020.02261","volume":"40","author":"B Andraka-Christou","year":"2021","unstructured":"Andraka-Christou B. Addressing racial and ethnic disparities in the use of medications for opioid use disorder. Health Aff. 2021;40(6):920\u20137.","journal-title":"Health Aff"},{"key":"682_CR25","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1108\/S1057-6290(2012)0000014008","volume-title":"Critical perspectives on addiction","author":"H Hansen","year":"2012","unstructured":"Hansen H, Roberts SK. Two tiers of biomedicalization: Methadone, buprenorphine, and the racial politics of addiction treatment. In: Netherland J, editor. Critical perspectives on addiction. Advances in medical sociology. Volume 14, 1 ed. Bingley: Emerald Group Publishing Limited; 2012. pp. 79\u2013102.","edition":"1"},{"issue":"3","key":"682_CR26","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s11414-013-9341-3","volume":"40","author":"HB Hansen","year":"2013","unstructured":"Hansen HB, Siegel CE, Case BG, Bertollo DN, DiRocco D, Galanter M. Variation in use of buprenorphine and methadone treatment by racial, ethnic, and income characteristics of residential social areas in New York City. J Behav Health Serv Res. 2013;40(3):367\u201377.","journal-title":"J Behav Health Serv Res"},{"issue":"9","key":"682_CR27","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1001\/jamapsychiatry.2019.0876","volume":"76","author":"PA Lagisetty","year":"2019","unstructured":"Lagisetty PA, Ross R, Bohnert A, Clay M, Maust DT. Buprenorphine treatment divide by race\/ethnicity and payment. JAMA Psychiatry. 2019;76(9):979.","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"682_CR28","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1080\/10550887.2016.1100960","volume":"35","author":"C Timko","year":"2016","unstructured":"Timko C, Schultz NR, Cucciare MA, Vittorio L, Garrison-Diehn C. Retention in medication-assisted treatment for opiate dependence: A systematic review. J Addict Dis. 2016;35(1):22\u201335.","journal-title":"J Addict Dis"},{"issue":"2","key":"682_CR29","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1001\/jamapsychiatry.2018.3126","volume":"76","author":"ND Volkow","year":"2019","unstructured":"Volkow ND, Jones EB, Einstein EB, Wargo EM. Prevention and treatment of opioid misuse and addiction: A review. JAMA Psychiatry. 2019;76(2):208.","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"682_CR30","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/add.12333","volume":"109","author":"YI Hser","year":"2014","unstructured":"Hser YI, Saxon AJ, Huang D, Hasson A, Thomas C, Hillhouse M, et al. Treatment retention among patients randomized to buprenorphine\/naloxone compared to methadone in a multi-site trial. Addiction. 2014;109(1):79\u201387.","journal-title":"Addiction"},{"key":"682_CR31","doi-asserted-by":"publisher","first-page":"107113","DOI":"10.1016\/j.addbeh.2021.107113","volume":"124","author":"M Hochheimer","year":"2022","unstructured":"Hochheimer M, Unick GJ. Systematic review and meta-analysis of retention in treatment using medications for opioid use disorder by medication, race\/ethnicity, and gender in the United States. Addict Behav. 2022;124:107113.","journal-title":"Addict Behav"},{"issue":"2","key":"682_CR32","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1001\/jama.2021.7374","volume":"326","author":"JM Donohue","year":"2021","unstructured":"Donohue JM, Jarlenski MP, Medicaid Outcomes Distributed Research Network (MODRN). Use of medications for treatment of opioid use disorder among US Medicaid enrollees in 11 states, 2014\u20132018. JAMA J Am Med Assoc. 2021;326(2):154\u201364. https:\/\/doi.org\/10.1001\/jama.2021.7374.","journal-title":"JAMA J Am Med Assoc"},{"issue":"9","key":"682_CR33","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1377\/hlthaff.2025.00253","volume":"44","author":"K Shen","year":"2025","unstructured":"Shen K, Thornburg B, Kennedy-Hendricks A, Meiselbach MK. Medicaid enrollees with opioid use disorder were more likely to receive medication treatment than commercial enrollees. Health Aff. 2025;44(9):1092\u2013101. https:\/\/doi.org\/10.1377\/hlthaff.2025.00253.","journal-title":"Health Aff"},{"key":"682_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/SAR.S304566","volume":"13","author":"A Cheetham","year":"2022","unstructured":"Cheetham A, Picco L, Barnett A, Lubman DI, Nielsen S. The impact of stigma on people with opioid use disorder, opioid treatment, and policy. SAR. 2022;13:1\u201312.","journal-title":"SAR"},{"issue":"14","key":"682_CR35","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1080\/10826084.2021.1975749","volume":"56","author":"EF Madden","year":"2021","unstructured":"Madden EF, Prevedel S, Light T, Sulzer SH. Intervention stigma toward medications for opioid use disorder: A systematic review. Subst Use Misuse. 2021;56(14):2181\u2013201.","journal-title":"Subst Use Misuse"},{"key":"682_CR36","doi-asserted-by":"publisher","first-page":"108488","DOI":"10.1016\/j.jsat.2021.108488","volume":"130","author":"A Burgess","year":"2021","unstructured":"Burgess A, Bauer E, Gallagher S, Karstens B, Lavoie L, Ahrens K, et al. Experiences of stigma among individuals in recovery from opioid use disorder in a rural setting: A qualitative analysis. J Subst Abuse Treat. 2021;130:108488.","journal-title":"J Subst Abuse Treat"},{"issue":"10","key":"682_CR37","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1080\/10826084.2021.1936051","volume":"56","author":"TH Witte","year":"2021","unstructured":"Witte TH, Jaiswal J, Mumba MN, Mugoya GCT. Stigma surrounding the use of medically assisted treatment for opioid use disorder. Subst Use Misuse. 2021;56(10):1467\u201375.","journal-title":"Subst Use Misuse"},{"key":"682_CR38","doi-asserted-by":"publisher","first-page":"100029","DOI":"10.1016\/j.rcsop.2021.100029","volume":"2","author":"A Cernasev","year":"2021","unstructured":"Cernasev A, Hohmeier KC, Frederick K, Jasmin H, Gatwood J. A systematic literature review of patient perspectives of barriers and facilitators to access, adherence, stigma, and persistence to treatment for substance use disorder. Exploratory Res Clin Social Pharm. 2021;2:100029.","journal-title":"Exploratory Res Clin Social Pharm"},{"key":"682_CR39","doi-asserted-by":"crossref","unstructured":"Hyder A, Lee J, Dundon A, Southerland LT, All D, Hammond G, et al. Opioid treatment deserts: concept development and application in a US Midwestern urban county. PLoS ONE. 2021;16(5):e0250324.","DOI":"10.1371\/journal.pone.0250324"},{"key":"682_CR40","doi-asserted-by":"publisher","first-page":"114992","DOI":"10.1016\/j.socscimed.2022.114992","volume":"302","author":"P Mitchell","year":"2022","unstructured":"Mitchell P, Samsel S, Curtin KM, Price A, Turner D, Tramp R, et al. Geographic disparities in access to Medication for Opioid Use Disorder across US census tracts based on treatment utilization behavior. Soc Sci Med. 2022;302:114992.","journal-title":"Soc Sci Med"},{"issue":"8","key":"682_CR41","doi-asserted-by":"publisher","first-page":"e2118487","DOI":"10.1001\/jamanetworkopen.2021.18487","volume":"4","author":"E Weintraub","year":"2021","unstructured":"Weintraub E, Seneviratne C, Anane J, Coble K, Magidson J, Kattakuzhy S, et al. Mobile telemedicine for buprenorphine treatment in rural populations with opioid use disorder. JAMA Netw Open. 2021;4(8):e2118487.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"682_CR42","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s11606-007-0129-0","volume":"22","author":"BA Moore","year":"2007","unstructured":"Moore BA, Fiellin DA, Barry DT, Sullivan LE, Chawarski MC, O\u2019Connor PG, et al. Primary care office-based buprenorphine treatment: Comparison of heroin and prescription opioid dependent patients. J GEN INTERN MED. 2007;22(4):527\u201330.","journal-title":"J GEN INTERN MED"},{"issue":"8","key":"682_CR43","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1111\/ajad.12641","volume":"26","author":"M Gonzalez","year":"2017","unstructured":"Gonzalez M, Shahanaghi A, DiGirolamo GJ, Gonzalez G. Buprenorphine-naloxone treatment responses differ between young adults with heroin and prescription opioid use disorders: Buprenorphine Treatment for Young Adults With opioid Use. Am J Addict. 2017;26(8):838\u201344.","journal-title":"Am J Addict"},{"issue":"1\u20132","key":"682_CR44","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.drugalcdep.2008.10.015","volume":"101","author":"GA Subramaniam","year":"2009","unstructured":"Subramaniam GA, Stitzer MA. Clinical characteristics of treatment-seeking prescription opioid vs. heroin-using adolescents with opioid use disorder. Drug Alcohol Depend. 2009;101(1\u20132):13\u20139.","journal-title":"Drug Alcohol Depend"}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-026-00682-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-026-00682-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-026-00682-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:47:23Z","timestamp":1789087643000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13722-026-00682-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["682"],"URL":"https:\/\/doi.org\/10.1186\/s13722-026-00682-2","relation":{},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"assertion":[{"value":"18 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was reviewed and approved by the Medical University of South Carolina Institutional Review Board (Protocol #00102868) and it was exempt from full IRB review. The study involved retrospective analysis of electronic health records and did not involve direct interaction with individuals as research participants. Records were de-identified prior to investigator access through the institutional honest broker system; therefore, informed consent was not required.","order":1,"name":"Ethics","label":"Ethics and approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Consent from individual patients was not obtained as no identifiable information is reported.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"67"}}